CCO Independent Conference Coverage

2006 Annual Meeting of the American Association for the Study of Liver Diseases*

October 27-31, 2006 | Boston, Massachusetts

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Clinical Updates in HBV Treatment

Track 1 of 3

Faculty:
	Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Robert G. Gish, MD Marion G. Peters, MD

Advances in HCV Treatment: 2006

Track 2 of 3

Faculty:
	Nezam H. Afdhal, MD, FRCPI Karen L. Lindsay, MD, MMM Mitchell L. Shiffman, MD

Highlight on Special Hepatic Issues and Populations

Track 3 of 3

Capsule Summaries

Expert Analysis

Faculty:
	Raymond T. Chung, MD Mark S. Sulkowski, MD Norah Terrault, MD, MPH

Expert Highlights

Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, discusses several topics of interest in the field of HBV treatment. In particular data on the benefits of extension of entecavir therapy; optimization of therapy based on early viral suppression; long term benefit of 48 week pegylated interferon treatment, and incidence and role of resistance in treatment modification are reviewed. (9 minutes)

Download Audio

Nezam H. Afdhal, MD, FRCPI, discusses the top line HCV data presented at the meeting with particular focus on specifically targeted antiviral therapy for HCV and how to combine novel therapeutics with other agents both approved and those in clinical development. (5 minutes)

Download Audio

Raymond T. Chung, MD, describes a new agent for the treatment of HCV/HIV coinfection, survival and prognostic factors in a cohort of HCV/HIV coinfected individuals, and the use of HCC down-staging to obtain transplantation candidacy. (11 minutes)

Download Audio

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.